Originally, the BIVF was designed to put investments of up to €10-15m into early stage companies focused on immunomodulation, tissue regeneration, small and large molecule drugs, and new therapeutic modalities. The fund, launched in 2010, had a volume of €100m, 22 portfolio companies from which already one exited (Okairos).
{iframe}https://european-biotechnology.com/up-to-date/latest-news/news/boehringer-ingelheim-expands-venture-funds-to-eur250m.html{/iframe}